实用肝脏病杂志 ›› 2026, Vol. 29 ›› Issue (2): 213-216.doi: 10.3969/j.issn.1672-5069.2026.02.013

• 非酒精性脂肪性肝病 • 上一篇    下一篇

非酒精性脂肪性肝病合并药物性肝损伤患者临床特征分析*

严云, 张玉霞, 王雪婷, 唐晨湘   

  1. 226001 江苏省南通市第四人民医院重症医学科(严云,张玉霞,王雪婷);南通大学附属南通第三医院药剂科(唐晨湘)
  • 收稿日期:2025-11-04 出版日期:2026-03-10 发布日期:2026-03-13
  • 作者简介:严云,女,34岁,大学本科,主治医师。E-mail:15962950293@163.com
  • 基金资助:
    *江苏省自然科学基金青年基金资助项目(编号:BK20210430)

Clinical features of patients with drug-induced liver injury with underlying non-alcoholic fatty liver disease

Yan Yun, Zhang Yuxia, Wang Xueting, et al   

  1. Intensive Care Unit, Fourth People's Hospital, Nantong 226001, Jiangsu Province, China
  • Received:2025-11-04 Online:2026-03-10 Published:2026-03-13

摘要: 目的 分析比较非酒精性脂肪性肝病(NAFLD)合并药物性肝损伤(DILI)与单纯DILI患者的临床特征差异。方法 2023年1月~2025年8月我院诊治的31例NAFLD合并DILI和52例DILI患者,常规停止可疑药物,给予护肝处理。计算胰岛素抵抗指数(HOMA-IR)和肝纤维化4因子指数(FIB-4),使用FibroScan 502瞬时弹性成像仪行肝脏硬度检测(LSM)和受控衰减参数(CAP)。结果 NAFLD合并DILI组BMI、合并糖尿病、高脂血症、高血压和多药应用占比显著高于DILI组(均P<0.05),用药时间显著长于DILI组(P<0.05);NAFLD合并DILI组血清转氨酶和血脂水平显著高于DILI组(P<0.05);HOMA-IR、FIB-4、CAP和LSM分别为(3.9±1.5)、(2.8±0.9)、(291.4±33.7)dB/m和(9.6±3.8)kPa,均显著高于DILI组【分别为(2.7±1.1)、(2.0±0.8)、(257.2±14.9)dB/m和(7.1±2.5)kPa,P<0.05】;肝细胞型、胆汁淤积型和混合型占比分别为58.1%、19.3%和22.6%,与DILI组的80.8%、7.7%和11.5%比,差异显著(P<0.05);血生化恢复时间为40.4(25.5,75.2)d,显著慢于DILI组【27.1(18.7,45.9)d,P<0.05】,住院日为13.3(9.2,22.6)d,显著长于DILI组【9.4(6.5,15.7)d,P<0.05】,转为慢性占比为19.3%,显著高于DILI组的5.5%(P<0.05)。结论 NAFLD合并DILI患者基础疾病多,肝损伤表现重,临床恢复慢,需要研究合理的管理措施。

关键词: 药物性肝损伤, 非酒精性脂肪性肝病, 临床特征, 转归

Abstract: Objective The aim of this study was to summarize the clinical features of patients with drug-induced liver injury (DILI) with underlying non-alcoholic fatty liver disease (NAFLD). Methods 31 patients with DILI with concomitant NAFLD and 52 patients with DILI alone were encountered in our hospital between January 2023 and August 2025, homestasis model assessment for insulin resistance (HOMA-IR) and fibrosis based on 4 factors(FIB-4) were calculated, and liver stiffness measurement (LSM) and controlled attenuation parameter (CAP) were detected by FibroScan 502. Results Body mass index, percentages of underlying diabetes, hyperlipidemia, hypertension and multiple medicine administration, and taking medicine time in patients with NAFLD and DILI were much greater or higher or longer than in patients with patients with DILI(all P<0.05); serum ALT and lipid levels were much higher than in those with DILI(P<0.05); HOMA-IR, FIB-4, CAP and LSM were (3.9±1.5), (2.8±0.9), (291.4±33.7)dB/m and (9.6±3.8)kPa, all much higher than [(2.7±1.1), (2.0±0.8), (257.2±14.9)dB/m and (7.1±2.5)kPa, respectively, P<0.05] in those with DILI; percentages of hepatocyte injury type, cholestasis type and mixed type were 58.1%, 19.3% and 22.6%,significantly different as compared to 80.8%, 7.7% and 11.5% in those with DILI (P<0.05); time for blood biochemical parameter recovery was 40.4(25.5,75.2)d,much longer than [27.1(18.7,45.9)d,P<0.05],hospital stay was 13.3(9.2,22.6)d,much longer than [9.4(6.5,15.7)d,P<0.05],and percentage of chronicity was 19.3%,much higher than 5.5%(P<0.05) in patients with DILI. Conclusion Patients with NAFLD and DILI should be carefully managed clinically, as they have much more underlying diseases, relatively severe manifestations and much slower recovery.

Key words: Drug-induced liver injury, Non-alcoholic fatty liver disease, Clinical features, Outcomes